Essent Group Inc (ESNT) Jumps 6.53% on February 17

Equities Staff  |

Essent Group Inc (ESNT) was among the biggest gainers on the Russell 2000 for Wednesday February 17 as the stock popped 6.53% to $18.27, representing a gain of $1.12 per share. Some 503,721 shares traded hands on 4,288 trades, compared with an average daily volume of 577,574 shares out of a total float of 92.65 million. The stock opened at $17.28 and traded with an intraday range of $18.40 to $17.17.

After today's gains, Essent Group Inc reached a market cap of $1.69 billion. Essent Group Inc has had a trading range between $29.67 and $16.49 over the last year, and it had a 50-day SMA of $20.31 and a 200-day SMA of $24.81.

The stock has a P/E Ratio of 10.

Essent Group Ltd provides credit protection to lenders and mortgage investors by covering a portion of the unpaid principal balance of a mortgage in the event of a default.

Essent Group Inc is based out of Hamilton, and has some 364 employees. Its CEO is Mark A. Casale.

For a complete fundamental analysis analysis of Essent Group Inc, check out’s Stock Valuation Analysis report for ESNT. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.